Physician profile
Premilla Mendonca
NPI 1619417300
$1,799.62
in general payments reported to CMS, 2019-2025
25 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $235 · 2023: $325 · 2024: $54.38 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.78 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $423.00 | 2021-2023 | Jakafi |
| Pharmacosmos Therapeutics INC. | $257.39 | 2023-2025 | Monoferric |
| Pfizer INC. | $185.99 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $124.94 | 2021 | |
| Eisai INC. | $124.22 | 2025 | |
| Convatec INC. | $123.89 | 2023 | |
| Merck Sharp & Dohme LLC | $66.96 | 2021-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $66.11 | 2021 | |
| Bard Peripheral Vascular, INC. | $62.46 | 2022 | |
| Amgen INC. | $56.88 | 2021-2025 | |
| Astellas Pharma US INC | $42.19 | 2021 | |
| Daiichi Sankyo INC. | $34.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.72 | 2023-2024 | |
| Janssen Biotech, INC. | $29.81 | 2022-2023 | Erleada |
| Olympus America INC. | $20.70 | 2024 | Visera Elite II Video System Center |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $19.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.71 | 2023 | Ninlaro |
| Astrazeneca Pharmaceuticals LP | $16.43 | 2023 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $16.31 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.74 | 2021 | |
| Morphosys, US INC. | $14.56 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $12.97 | 2022 | |
| Array Biopharma INC | $12.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.92 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Premilla Mendonca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.